middle.news
Cynata Completes Key Phase 2 Milestone in aGvHD Trial, Data Due June
9:08am on Monday 30th of March, 2026 AEDT
•
Healthcare
Read Story
Cynata Completes Key Phase 2 Milestone in aGvHD Trial, Data Due June
9:08am on Monday 30th of March, 2026 AEDT
Key Points
100-day primary evaluation period completed for all 65 trial participants
Phase 2 trial of CYP-001 targets acute graft versus host disease (aGvHD)
Trial is randomised, double-blind, placebo-controlled across Australia, USA, Europe
Primary endpoint: Overall Response Rate at Day 28; results expected June 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CYNATA THERAPEUTICS (ASX:CYP)
OPEN ARTICLE